Inhaled Nitric Oxide for Fibrotic Interstitial Lung Disease: A Step Forward
Ann Am Thorac Soc
.
2022 Apr;19(4):536-538.
doi: 10.1513/AnnalsATS.202110-1160ED.
Authors
Yet H Khor
1
2
3
4
,
Ayodeji Adegunsoye
5
6
Affiliations
1
Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia.
2
Institute for Breathing and Sleep, Heidelberg, Victoria, Australia.
3
Central Clinical School, Monash University, Melbourne, Victoria, Australia.
4
Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
5
Section of Pulmonary & Critical Care, University of Chicago Medicine, Chicago, Illinois; and.
6
Committee on Genetics, Genomics and Systems Biology; The University of Chicago, Chicago, Illinois.
PMID:
35363132
PMCID:
PMC8996278
DOI:
10.1513/AnnalsATS.202110-1160ED
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
Comment
MeSH terms
Humans
Lung
Lung Diseases, Interstitial* / drug therapy
Nitric Oxide*
Substances
Nitric Oxide
Grant support
K23 HL146942/HL/NHLBI NIH HHS/United States